← board
IPHA
distress 2/10 · well-funded / low risk$1.79+1%today-25% from 52w high
Revenue
pre-revenue
Liquidity
$45M
Runway
1.4 yrs
Shares 1y
0%
Price & events
+0.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.8%
1D
+0.8%
1W
-5.3%
1M
+30.7%
3M
+0.0%
6M
-9.6%
1Y
-19.4%
2Y
-45.8%
5Y
-58.5%
All
Overview
- Market Cap
- $167.76M
- Enterprise Value
- $153.34M
- Volume
- 1.21K
- 52 Week Range
- $1.17 – $2.38
- Total Shares
- 93.72M
- Float Shares
- 70.54M
- Short %
- 0.19%
- % Held by Insiders
- 1.67%
- % Held by Institutions
- 0.45%
- RVOL
- 0.05x
- Beta
- 0.88
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-09-17earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 93,719,323 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-07HC Wainwright & Co.Buy
- 2025-10-29HC Wainwright & Co.Neutral → Buy
- 2025-10-29BTIGBuy
- 2025-09-18Leerink PartnersOutperform → Market Perform
- 2025-09-18HC Wainwright & Co.Buy → Neutral
- 2025-04-24HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.